Bisphosphonate related osteonecrosis of the jaws.

J Ayub Med Coll Abbottabad

Department of Oral & Maxillofacial Surgery, de'Montmorency College of Dentistry/Punjab Dental Hospital, Lahore, Pakistan.

Published: April 2012

Bisphosphonates are used widely for a variety of bone conditions, most notably intravenous bisphosphonate in the treatment of metastatic bone lesions and multiple myeloma and oral bisphosphonates for osteoporosis. Recently, a peculiar form of osteonecrosis limited to the jaws has been discovered especially with the use of intravenous bisphosphonates. We review briefly the mechanism of action of these drugs, the clinical features and staging of the disease, prevention strategies and management options.

Download full-text PDF

Source

Publication Analysis

Top Keywords

bisphosphonate osteonecrosis
4
osteonecrosis jaws
4
jaws bisphosphonates
4
bisphosphonates variety
4
variety bone
4
bone conditions
4
conditions notably
4
notably intravenous
4
intravenous bisphosphonate
4
bisphosphonate treatment
4

Similar Publications

Beta-adrenergic receptor antagonist propranolol prevents bisphosphonate-related osteonecrosis of the jaw by promoting osteogenesis.

J Dent Sci

January 2025

State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Background/purpose: Bisphosphonate-related osteonecrosis of the jaw (BRONJ), a complication arising from the use of bisphosphonates (BPs), inflicts long-term suffering on patients. Currently, there is still a lack of effective treatments. This study aimed to explore the preventive effects of propranolol (PRO) on BRONJ in vitro and in vivo, given PRO's potential in bone health enhancement.

View Article and Find Full Text PDF

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but potentially severe condition that significantly affects the quality of life of patients with cancer. This study evaluated MRONJ in patients with cancer treated with zoledronic acid (ZOA) and denosumab (Dmab).

Methods: The survey investigated patients who were diagnosed with MRONJ at the Department of Oral and Maxillofacial Surgery after receiving either ZOA or Dmab at the Saitama Medical Center, Saitama Medical University, between April 1, 2022, and March 31, 2023.

View Article and Find Full Text PDF

Objectives: In advanced stages of osteoradionecrosis, medication-related osteonecrosis of the jaw, and osteomyelitis, a resection of sections of the mandible may be unavoidable. The determination of adequate bony resection margins is a fundamental problem because bony resection margins cannot be secured intraoperatively. Single-photon emission computed tomography (SPECT-CT) is more accurate than conventional imaging techniques in detecting inflammatory jaw pathologies.

View Article and Find Full Text PDF

Rationale: Osteoporosis is an abnormal reduction in bone mass and bone deterioration, leading to increased fracture risk. Alendronate belongs to the bisphosphonate class of drugs, which inhibit bone resorption by interfering with the activity of osteoclasts (bone cells that break down bone tissue). This is an update of a Cochrane review first published in 2008.

View Article and Find Full Text PDF

Introduction: Osteonecrosis of the jaw resulting from the adverse effects of medical treatments is known as medication-related osteonecrosis of the jaws (MRONJ). The knowledge of dental professionals about this condition is crucial in addressing it on a regional and global scale. This study aims to assess the knowledge and awareness of MRONJ among dental practitioners in Mumbai.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!